Stable Coronary Heart Disease Angina pectoris
Conditions
Interventions
the placebo group:Western standard treatment plus placebo (just like tongmai Yang Xin Wan, production units: Tianjin Zhongxin Pharmaceutical Group Co., Ltd. lerentang pharmaceutical) medicine method:
medication time: 12 weeks.
the experimental group:Western standard treatment + tongmai Yang Xin Wan (production units: Tianjin Zhongxin Pharmaceutical Group Co., Ltd. lerentang pharmaceutical), medication methods: 40 / times, 2
taking time: 12 weeks
Sponsors
Institute of Basic Theory of TCM, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. in line with Western diagnostic criteria for chronic stable angina; 2. TCM belongs to Qi and Yin deficiency syndrome of angina pectoris; 3. NYHA functional class grade II or III; 4. To be aged 50 to 75 years; 5. signed informed consent; 6. there are indicators of myocardial injury: BNP more than 500ng/L; echocardiography E/A less than 1 (without high blood pressure, heart disease); echocardiography Action figure LVEF <50% (exclude hypertension, rheumatic heart disease, cardiomyopathy); sensitive troponin exceed the upper limit of normal. Note: meet from 1 to 6, before inclusion.
Exclusion criteria
Exclusion criteria: 1. Conducted a coronary revascularization within 3 months; 2. resting ECG has following abnormalities: complete left bundle branch block, WPW syndrome, ventricular pacing; 3. merge uncontrolled symptomatic heart failure or left ventricular ejection fraction echocardiography prompted less than 40%; 4. the need for treatment of rapid or slow arrhythmias; 5. the known renal insufficiency, male serum creatinine more than 2.5mg/dl, females more than 2.0mg/dl; known liver dysfunction, ALT more than 2 times the normal value; 6. combined with tumor, primary hematopoietic system and other serious diseases and the mentally ill; 7. made surgery and bleeding tendencies within 4 weeks; 8. Participating in other clinical trials are within 8 months; 9. known allergy or allergic constitution to medicines of the preparations; 10. himself or immediate family who have previously taken fleece-flower root and its preparations history of liver dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BNP and high sensitive troponin absolute value;EF value, E / A (quantitative detection);Quality of life (Seattle Angina Scale);TCM Syndrome;The incidence of major cardiovascular events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic data: age, gender, height, weight, ethnicity, occupation.;Clinical data: history, course, treatment history, physical examination, and other comorbidities and medication;Vital signs (temperature, heart rate, respiration, pulse, blood pressure);Laboratory tests: blood and urine routine tests; liver function (ALT, AST, ALP, gama-GGT, TBIL); renal function (Cr, BUN); coagulation (PT, TT, APTT, FIB).; | — |
Countries
China
Contacts
Public ContactHU Jingqing
Outcome results
None listed